Compare CSW & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSW | EWTX |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | United States | United States |
| Employees | N/A | 127 |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 4.3B |
| IPO Year | 2014 | 2021 |
| Metric | CSW | EWTX |
|---|---|---|
| Price | $295.48 | $39.39 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 14 |
| Target Price | ★ $351.86 | $52.62 |
| AVG Volume (30 Days) | 89.8K | ★ 1.3M |
| Earning Date | 10-29-2026 | 11-05-2026 |
| Dividend Yield | ★ 0.41% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.04 | N/A |
| Revenue | ★ $1,082,549,000.00 | N/A |
| Revenue This Year | $18.51 | N/A |
| Revenue Next Year | $4.26 | N/A |
| P/E Ratio | $97.07 | ★ N/A |
| Revenue Growth | ★ 23.25 | N/A |
| 52 Week Low | $236.66 | $15.23 |
| 52 Week High | $355.48 | $48.51 |
| Indicator | CSW | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 49.32 | 46.70 |
| Support Level | $282.14 | $37.33 |
| Resistance Level | $293.90 | $41.22 |
| Average True Range (ATR) | 8.19 | 1.74 |
| MACD | 0.99 | 0.25 |
| Stochastic Oscillator | 52.06 | 65.99 |
CSW Industrials Inc is a diversified industrial growth company with well-established, scalable platforms & domain expertise across three segments: Contractor Solutions, Engineered Building Solutions, & Specialized Reliability Solutions. The company's Contractor Solutions segment involves manufacturing efficient & performance-enhancing products for residential & commercial HVAC/R & plumbing applications, which are designed for professional end-use customers. The majority of the company's revenue is generated from the Contractor Solutions segment in the U.S. markets. products include mechanical products for heating, ventilation, air conditioning, & refrigeration, plumbing products, grilles, registers, & diffusers, building safety solutions, & high-performance specialty lubricants & sealants.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.